Clinical Trial Update: Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating intravesical recombinant Bacillus Calmette-Guérin (BCG) followed by perioperative chemo-immunotherapy for muscle-inva…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Muscle-invasive Bladder Cancer

Drugs mentioned

• Bacillus Calmette-Guérin (BCG) (Bacillus Calmette-Guérin)
• Perioperative chemo-immunotherapy (unspecified agents)

Snippet

Sponsor: Swiss Cancer Institute | Conditions: Bladder Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING